PA8808201A1 - Moduladores imidazolo-,oxazolo-, y tiazolopirimidina del trpvi - Google Patents
Moduladores imidazolo-,oxazolo-, y tiazolopirimidina del trpviInfo
- Publication number
- PA8808201A1 PA8808201A1 PA20088808201A PA8808201A PA8808201A1 PA 8808201 A1 PA8808201 A1 PA 8808201A1 PA 20088808201 A PA20088808201 A PA 20088808201A PA 8808201 A PA8808201 A PA 8808201A PA 8808201 A1 PA8808201 A1 PA 8808201A1
- Authority
- PA
- Panama
- Prior art keywords
- imidazolo
- modulators
- thiazolopirimidine
- trpvi
- oxazolo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
SE DESCRIBEN CIERTOS COMPUESTOS DE IMIDAZOLO-,Y TIAZOLOPIRÍMIDINA MODULADORES DEL TRPV1.LOS COMPUESTOS SE PUEDEN UTILIZAR EN COMPOSICIONES FARMACÉUTICAS Y MÉTODOS PARA EL TRATAMIENTO DE ESTADOS DE ENFERMEDAD,TRASTORNOS Y CONDICIONES MEDIADAS POR LA ACTIVIDAD DE TRPV1,TALES COMO DOLOR,ARTRITIS,PRURITO,TOS,ASMA O ENFERMEDAD INFLAMATORIA INTESTINAL,
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1415807P | 2007-12-17 | 2007-12-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
PA8808201A1 true PA8808201A1 (es) | 2010-05-26 |
Family
ID=40754075
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PA20088808201A PA8808201A1 (es) | 2007-12-17 | 2008-12-17 | Moduladores imidazolo-,oxazolo-, y tiazolopirimidina del trpvi |
Country Status (10)
Country | Link |
---|---|
US (4) | US8288397B2 (es) |
EP (1) | EP2224929B1 (es) |
JP (1) | JP5562865B2 (es) |
AR (1) | AR069777A1 (es) |
CL (1) | CL2008003749A1 (es) |
PA (1) | PA8808201A1 (es) |
PE (1) | PE20091102A1 (es) |
TW (1) | TW200942549A (es) |
UY (1) | UY31540A1 (es) |
WO (1) | WO2009078999A1 (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20091102A1 (es) | 2007-12-17 | 2009-07-25 | Janssen Pharmaceutica Nv | Moduladores imidazolo-, oxazolo-, y tiazolopirimidina del trpv1 |
WO2011003530A2 (de) * | 2009-07-07 | 2011-01-13 | Bayer Cropscience Ag | Verfahren zur herstellung von (2,4-dimethylbiphenyl-3-yl)essigsäuren, deren ester sowie zwischenverbindungen |
WO2011078143A1 (ja) * | 2009-12-22 | 2011-06-30 | 塩野義製薬株式会社 | ピリミジン誘導体およびそれらを含有する医薬組成物 |
WO2012078909A1 (en) * | 2010-12-08 | 2012-06-14 | Proteostasis Therapeutics, Inc. | Thiazolpyrimidine proteostasis regulators |
ES2591129T3 (es) | 2012-05-21 | 2016-11-25 | Bayer Pharma Aktiengesellschaft | Tienopirimidinas |
US9675612B2 (en) * | 2013-03-06 | 2017-06-13 | Bayer Pharma Aktiengesellschaft | Substituted thiazolopyrimidines |
CA2925211A1 (en) | 2013-09-27 | 2015-04-02 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
TWI703150B (zh) * | 2015-06-04 | 2020-09-01 | 美商庫拉腫瘤技術股份有限公司 | 用於抑制menin及mll蛋白之交互作用的方法及組合物 |
IT201600070952A1 (it) * | 2016-07-07 | 2018-01-07 | Univ Degli Studi Di Ferrara | NUOVI TIAZOLO[5,4-d]PIRIMIDIN DERIVATI QUALI AGONISTI INVERSI DEI RECETTORI A2A DELL’ADENOSINA |
US20200215085A1 (en) * | 2017-07-19 | 2020-07-09 | Uti Limited Partnership | Method to Abate Acute Airway Hypersensitivity and Asthma Attacks |
GB201811169D0 (en) * | 2018-07-06 | 2018-08-29 | Kancera Ab | New compounds |
WO2021102330A1 (en) * | 2019-11-21 | 2021-05-27 | Synventa Llc | Compositions and methods for treatment of pain |
Family Cites Families (121)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4160834A (en) | 1977-03-09 | 1979-07-10 | Eli Lilly And Company | 1-(Substituted benzoyl)-3-(substituted pyrazinyl)ureas |
JPH03167178A (ja) | 1989-11-24 | 1991-07-19 | Taiji Nakayama | ピリミジン誘導体 |
JPH03255077A (ja) | 1990-03-01 | 1991-11-13 | Taiji Nakayama | ピリミジン誘導体およびそれを有効成分とする血小板凝集阻止剤 |
SE468719B (sv) | 1991-07-02 | 1993-03-08 | Saab Scania Ab | Arrangemang foer braensleledning vid foerbraenningsmotor |
AU3427093A (en) | 1992-01-15 | 1993-08-03 | E.I. Du Pont De Nemours And Company | Bridged heterocyclic fungicides |
JPH06172355A (ja) | 1992-04-14 | 1994-06-21 | Mect Corp | ピリミジン誘導体およびそれを有効成分とする血小板凝集阻止剤 |
JPH0625243A (ja) | 1992-07-08 | 1994-02-01 | Sankyo Co Ltd | 1−メチルカルバペネム誘導体の製造法 |
DE4332168A1 (de) | 1993-02-22 | 1995-03-23 | Thomae Gmbh Dr K | Cyclische Derivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
DE19624069A1 (de) | 1996-06-17 | 1997-12-18 | Thomae Gmbh Dr K | Benzazepinderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
US6150343A (en) | 1993-06-30 | 2000-11-21 | University Of Pittsburgh | Camptothecin analogs and methods of preparation thereof |
US5512563A (en) | 1993-07-29 | 1996-04-30 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
US5834461A (en) | 1993-07-29 | 1998-11-10 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
US5428040A (en) | 1993-08-31 | 1995-06-27 | The Du Pont Merck Pharmaceutical Company | Carbocyclic fused-ring quinolinecarboxylic acids useful as immunosuppressive agents |
AR002459A1 (es) | 1995-01-17 | 1998-03-25 | American Cyanamid Co | Antagonistas de vasopresina de benzacepina triciclicos, una composicion farmaceutica que los contiene, un metodo para tratar enfermedades y unprocedimiento para su preparacion. |
AR004010A1 (es) | 1995-10-11 | 1998-09-30 | Glaxo Group Ltd | Compuestos heterociclicos |
US5985799A (en) | 1995-11-17 | 1999-11-16 | E.I. Du Pont De Nemours And Company | Tricyclic herbicidal heterocycles |
US6107300A (en) | 1996-03-27 | 2000-08-22 | Dupont Pharmaceuticals | Arylamino fused pyrimidines |
WO1997047601A1 (fr) | 1996-06-11 | 1997-12-18 | Yoshitomi Pharmaceutical Industries, Ltd. | Composes heterocycliques fusionnes et leurs utilisations medicinales |
AU3296497A (en) | 1996-06-13 | 1998-01-07 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
EP0973778A1 (en) | 1997-03-07 | 2000-01-26 | Novo Nordisk A/S | 4,5,6,7-TETRAHYDRO-THIENO 3,2-c]PYRIDINE DERIVATIVES, THEIR PREPARATION AND USE |
ZA982368B (en) | 1997-03-27 | 1998-09-23 | Akzo Nobel Nv | New therapeutic combinations |
ATE356139T1 (de) | 1997-06-25 | 2007-03-15 | Pfizer | Dipeptidderivate zur förderung der sekretion von wachstumshormon |
US6232320B1 (en) | 1998-06-04 | 2001-05-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
US6358951B1 (en) | 1998-08-21 | 2002-03-19 | Pfizer Inc. | Growth hormone secretagogues |
CZ27399A3 (cs) | 1999-01-26 | 2000-08-16 | Ústav Experimentální Botaniky Av Čr | Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv |
JP2001097979A (ja) | 1999-07-28 | 2001-04-10 | Takeda Chem Ind Ltd | 縮合複素環化合物、その製造法および用途 |
US7160890B2 (en) | 1999-12-02 | 2007-01-09 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A3 receptor and uses thereof |
JP2001294572A (ja) | 2000-02-09 | 2001-10-23 | Dai Ichi Seiyaku Co Ltd | 新規スルホニル誘導体 |
EP1149583A3 (en) | 2000-04-13 | 2001-11-14 | Pfizer Products Inc. | Combinations of corticotropin releasing factor antagonists and growth hormone secretagogues |
DOP2001000154A (es) | 2000-05-25 | 2002-05-15 | Pfizer Prod Inc | Combinación de secretagogos de hormona del crecimiento y antidepresivos |
DE60140285D1 (de) | 2000-05-31 | 2009-12-10 | Pfizer Prod Inc | Verwendung von Wachstumshormonsekretagoga zur Förderung der Beweglichkeit des Verdauungstrakts |
IL143690A0 (en) | 2000-06-19 | 2002-04-21 | Pfizer Prod Inc | The use of growth hormone secretagogues to treat systemic lupus erythematosus and inflammatory bowel disease |
BR0111567A (pt) | 2000-06-28 | 2003-05-06 | Pfizer Prod Inc | Ligandos do receptor de melanocortina |
EP1181933A3 (en) | 2000-06-29 | 2002-04-10 | Pfizer Products Inc. | Use of growth hormone secretagogues for stimulating or increasing appetite |
IL143942A0 (en) | 2000-06-29 | 2002-04-21 | Pfizer Prod Inc | Use of growth hormone secretagogues for treatment of physical performance decline |
US6846813B2 (en) | 2000-06-30 | 2005-01-25 | Pharmacia & Upjohn Company | Compounds to treat alzheimer's disease |
DE60112942T2 (de) | 2000-06-30 | 2006-06-22 | Elan Pharmaceuticals, Inc., South San Francisco | Verbindungen zur behandlung der alzheimerischen krankheit |
US6369222B1 (en) | 2000-07-18 | 2002-04-09 | Hoffmann-La Roche Inc. | mGluR antagonists and a method for their synthesis |
IL144468A0 (en) | 2000-07-27 | 2002-05-23 | Pfizer Prod Inc | Use of growth hormone secretagogues for improvement of functional health status |
US6660731B2 (en) | 2000-09-15 | 2003-12-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
KR100876069B1 (ko) | 2000-09-15 | 2008-12-26 | 버텍스 파마슈티칼스 인코포레이티드 | 단백질 키나제 억제제로서 유용한 피라졸 화합물 및 이를 포함하는 약제학적 조성물 |
IL145540A0 (en) | 2000-09-28 | 2002-06-30 | Pfizer Prod Inc | Use of growth hormone secretagogues in conjunction with physical exercise |
ES2282299T3 (es) | 2000-10-20 | 2007-10-16 | EISAI R&D MANAGEMENT CO., LTD. | Compuestos aromaticos con anillos de nitrogeno como agentes anticancerigenos. |
MXPA03005610A (es) | 2000-12-21 | 2003-10-06 | Vertex Pharma | Compuestos de pirazol utiles como inhibidores de la proteina cinasa. |
EP2256104A1 (en) | 2000-12-27 | 2010-12-01 | Merck Patent GmbH | Process for the preparation of alpha-aminosubstituted carboxylic acid amides |
WO2002088079A2 (en) | 2001-05-01 | 2002-11-07 | Bristol-Myers Squibb Company | Dual inhibitors of pde 7 and pde 4 |
US7105667B2 (en) | 2001-05-01 | 2006-09-12 | Bristol-Myers Squibb Co. | Fused heterocyclic compounds and use thereof |
US6686352B2 (en) | 2001-05-18 | 2004-02-03 | Hoffmann-La Roche Inc. | Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives |
EP2336133A1 (en) | 2001-10-30 | 2011-06-22 | Conforma Therapeutics Corporation | Purine analogs having HSP90-inhibiting activity |
CA2468649C (en) | 2001-11-30 | 2009-03-10 | Schering Corporation | Adenosine a2a receptor antagonists |
MXPA04006882A (es) | 2002-01-17 | 2004-12-06 | Neurogen Corp | Analogos substituidos de quinazolin-4-ilamina como moduladores de receptores de capsaicina. |
JP2003321472A (ja) | 2002-02-26 | 2003-11-11 | Takeda Chem Ind Ltd | Grk阻害剤 |
US20030199514A1 (en) | 2002-03-27 | 2003-10-23 | Fryburg David A. | Methods for improving efficacy of treatment with growth hormone secretagogues |
JPWO2003104230A1 (ja) | 2002-06-07 | 2005-10-06 | 協和醗酵工業株式会社 | 二環性ピリミジン誘導体 |
CA2488562A1 (en) | 2002-06-27 | 2004-01-08 | F. Hoffmann-La Roche Ag | Synthesis of purine derivatives |
US20030139427A1 (en) | 2002-08-23 | 2003-07-24 | Osi Pharmaceuticals Inc. | Bicyclic pyrimidinyl derivatives and methods of use thereof |
GB0221828D0 (en) | 2002-09-20 | 2002-10-30 | Astrazeneca Ab | Novel compound |
US7384937B2 (en) | 2002-11-06 | 2008-06-10 | Bristol-Myers Squibb Co. | Fused heterocyclic compounds and use thereof |
US7265138B2 (en) | 2003-02-10 | 2007-09-04 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
US20040157645A1 (en) * | 2003-02-12 | 2004-08-12 | Smith Adrian David | System and method of operation an array antenna in a distributed wireless communication network |
AR045979A1 (es) | 2003-04-28 | 2005-11-23 | Astrazeneca Ab | Amidas heterociclicas |
WO2004108120A1 (en) | 2003-06-11 | 2004-12-16 | Pfizer Products Inc. | Use of growth hormone secretagogues for treatment of fibromyalgia |
DE602004023299D1 (de) | 2003-07-21 | 2009-11-05 | Pfizer Prod Inc | Nikotin abhängigkeit reduzierende heteroaryl kondensierte azapolycyclische verbindungen |
JP4808156B2 (ja) | 2003-08-05 | 2011-11-02 | バーテックス ファーマシューティカルズ インコーポレイテッド | 電位依存型イオンチャネルの阻害剤としての縮合ピリミジン化合物 |
JPWO2005014548A1 (ja) | 2003-08-08 | 2006-10-05 | 住友化学株式会社 | ジソピラミド遊離塩基の低融点型結晶の製造方法 |
US20070105865A1 (en) | 2003-09-09 | 2007-05-10 | Neurogen Corporation | Substituted bicyclic quinazolin-4-ylamine derivatives |
MXPA06003615A (es) | 2003-09-30 | 2006-06-05 | Amgen Inc | Ligandos del receptor vanilloide y su uso en tratamientos. |
WO2005033115A1 (en) | 2003-10-07 | 2005-04-14 | Astrazeneca Ab | New 2-substituted, 4-amino-thiazolo[4,5-d] pyrimidines, useful as chemokine receptor antagonists, esp. cx3cr1 |
US7816356B2 (en) | 2003-11-14 | 2010-10-19 | Daniel Yohannes | Aryl and heteroaryltetrahydrocyclobutapyrroles as nicotinic acetylcholine receptor ligands |
US20070135454A1 (en) | 2003-11-14 | 2007-06-14 | Tracy Bayliss | Bicyclic pyrimidin-4(3h)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1-receptor(vr1) |
JP2005162673A (ja) | 2003-12-03 | 2005-06-23 | Kyowa Hakko Kogyo Co Ltd | 二環性ピリミジン誘導体 |
US7312330B2 (en) | 2003-12-24 | 2007-12-25 | Renovis, Inc. | Bicycloheteroarylamine compounds as ion channel ligands and uses thereof |
TW200530235A (en) | 2003-12-24 | 2005-09-16 | Renovis Inc | Bicycloheteroarylamine compounds as ion channel ligands and uses thereof |
WO2005070929A1 (en) | 2004-01-23 | 2005-08-04 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
WO2005082865A1 (ja) | 2004-02-27 | 2005-09-09 | Astellas Pharma Inc. | 縮合二環性ピリミジン誘導体 |
JPWO2005095419A1 (ja) | 2004-04-01 | 2008-02-21 | 武田薬品工業株式会社 | チアゾロピリミジン誘導体 |
GB0412467D0 (en) | 2004-06-04 | 2004-07-07 | Astrazeneca Ab | Chemical compounds |
ITMI20041231A1 (it) | 2004-06-18 | 2004-09-18 | Pharmeste Srl | Antagonisti del recettore dei vanilloidi trpv1 |
ITMI20041566A1 (it) | 2004-07-30 | 2004-10-30 | Indena Spa | "trpv1 agonisti, formulazioni che li contengono e loro usi" |
FR2874015B1 (fr) | 2004-08-05 | 2006-09-15 | Sanofi Synthelabo | Derives de n-(1h-indolyl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique |
JP2006083085A (ja) | 2004-09-15 | 2006-03-30 | Kyowa Hakko Kogyo Co Ltd | 二環性ピリミジン誘導体の製造法およびその合成中間体 |
GB0420719D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
CN101068815B (zh) | 2004-10-04 | 2012-09-05 | 千禧药品公司 | 有效作为蛋白激酶抑制剂的内酰胺化合物 |
WO2006044762A2 (en) | 2004-10-15 | 2006-04-27 | Bayer Pharmaceuticals Corporation | Tetrahydro-5h-pyrimido[4,5-d]azepine derivatives useful for the treatment of diseases associated with the 5-ht2c receptor |
NZ555318A (en) | 2004-11-24 | 2011-01-28 | Abbott Lab | Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof |
US7725934B2 (en) | 2004-12-07 | 2010-05-25 | Cisco Technology, Inc. | Network and application attack protection based on application layer message inspection |
US20060128710A1 (en) | 2004-12-09 | 2006-06-15 | Chih-Hung Lee | Antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof |
US7521446B2 (en) | 2005-01-13 | 2009-04-21 | Signal Pharmaceuticals, Llc | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith |
JP2008528613A (ja) | 2005-01-25 | 2008-07-31 | ニューロジェン・コーポレーション | 置換ピリダジニル−及びピリミジニル−キノリン−4−イルアミン類縁体 |
US20080234252A1 (en) | 2005-05-18 | 2008-09-25 | Pfizer Inc | Compounds Useful in Therapy |
WO2006130469A1 (en) | 2005-05-27 | 2006-12-07 | Oregon Health & Science University | Stimulation of neurite outgrowth by small molecules |
PE20070171A1 (es) | 2005-06-30 | 2007-03-08 | Boehringer Ingelheim Int | GLICINAMIDAS SUSTITUIDAS CON EFECTO ANTITROMBOTICO E INHIBIDOR DEL FACTOR Xa |
US20070032473A1 (en) | 2005-07-19 | 2007-02-08 | Kai Gerlach | Substituted amides and their use as medicaments |
JP2009501731A (ja) | 2005-07-21 | 2009-01-22 | ニューサウス イノベーションズ ピティ リミテッド | 癌を治療する方法 |
US7598255B2 (en) | 2005-08-04 | 2009-10-06 | Janssen Pharmaceutica Nv | Pyrimidine compounds as serotonin receptor modulators |
CA2617760C (en) | 2005-08-04 | 2015-02-17 | Janssen Pharmaceutica N.V. | Pyrimidine compounds as serotonin receptor modulators |
JP5305905B2 (ja) | 2005-08-08 | 2013-10-02 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | チアゾロピリミジンキナーゼ阻害剤 |
US20070136603A1 (en) | 2005-10-21 | 2007-06-14 | Sensis Corporation | Method and apparatus for providing secure access control for protected information |
BRPI0618900A2 (pt) | 2005-11-22 | 2011-09-27 | Smithkline Beecham Corp | compostos calcilìticos |
JP4678685B2 (ja) | 2005-12-26 | 2011-04-27 | 株式会社吉野工業所 | エアゾール式液噴出器 |
DE102005062987A1 (de) | 2005-12-28 | 2007-07-05 | Grünenthal GmbH | Substituierte Propiolsäureamide und ihre Verwendung zur Herstellung von Arzneimitteln |
US20070155747A1 (en) | 2005-12-29 | 2007-07-05 | Kadmus Pharmaceuticals, Inc. | Inhibitors of fatty acid amide hydrolase |
US20070155707A1 (en) | 2005-12-29 | 2007-07-05 | Kadmus Pharmaceuticals, Inc. | Ionizable inhibitors of fatty acid amide hydrolase |
JP2009523748A (ja) | 2006-01-18 | 2009-06-25 | シエナ ビオテク ソシエタ ペル アチオニ | α7ニコチン性アセチルコリン受容体の調節物質およびそれらの治療への使用 |
EP1818330A1 (de) | 2006-02-14 | 2007-08-15 | Boehringer Ingelheim Pharma GmbH & Co.KG | Substituierte Prolinamide, deren Herstellung und deren Verwendung als Arzneimittel |
KR20080109841A (ko) | 2006-03-10 | 2008-12-17 | 뉴로젠 코포레이션 | 피페라지닐 옥소알킬 테트라히드로이소퀴놀린 및 관련유사체 |
EP1996577B1 (en) | 2006-03-21 | 2016-02-10 | Merck Sharp & Dohme Corp. | Heterocyclic substituted pyridine compounds with cxcr3 antagonist activity |
PE20080145A1 (es) | 2006-03-21 | 2008-02-11 | Janssen Pharmaceutica Nv | Tetrahidro-pirimidoazepinas como moduladores de trpv1 |
US7951829B2 (en) * | 2006-05-03 | 2011-05-31 | Janssen Pharmaceutica Nv | Benzimidazole modulators of VR1 |
AU2007254357B2 (en) | 2006-05-16 | 2011-07-21 | Merck Sharp & Dohme Corp. | Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes |
ES2350013T3 (es) * | 2006-05-18 | 2011-01-14 | F. Hoffmann-La Roche Ag | Derivados de tiazolo-pirimidina/piridina-urea como antagonistas de receptor de adenosina a2b. |
US20080051387A1 (en) | 2006-06-09 | 2008-02-28 | Yuelian Xu | Tetrahydropyrido[3,4-d]pyrimidines and related analogues |
TWI367112B (en) | 2006-06-30 | 2012-07-01 | Schering Corp | Immediate-release tablet formulations of a thrombin receptor antagonist |
KR20090042779A (ko) | 2006-06-30 | 2009-04-30 | 쉐링 코포레이션 | P53 활성을 증가시키는 치환된 피페리딘 및 이의 사용 |
US20080004253A1 (en) | 2006-06-30 | 2008-01-03 | Bryan James Branstetter | Thiazolopyrimidine modulators of TRPV1 |
MX2009000132A (es) | 2006-06-30 | 2009-01-26 | Schering Corp | Metodo para el uso de piperidinas sustituidas que incrementan la actividad de p53. |
WO2008024139A2 (en) | 2006-08-18 | 2008-02-28 | N.V. Organon | Inhibitors of fatty acid amide hydrolase |
CN101594870A (zh) | 2006-08-22 | 2009-12-02 | 康塞特医药品有限公司 | 4-氨基喹唑啉衍生物及其使用方法 |
JP2009007273A (ja) * | 2007-06-27 | 2009-01-15 | Ajinomoto Co Inc | ジアミノピリミジン化合物の製造方法 |
US20090156598A1 (en) | 2007-12-17 | 2009-06-18 | Lebsack Alec D | Imidazolopyrimidine modulators of TRPV1 |
PE20091102A1 (es) | 2007-12-17 | 2009-07-25 | Janssen Pharmaceutica Nv | Moduladores imidazolo-, oxazolo-, y tiazolopirimidina del trpv1 |
-
2008
- 2008-12-16 PE PE2008002082A patent/PE20091102A1/es not_active Application Discontinuation
- 2008-12-16 TW TW097148847A patent/TW200942549A/zh unknown
- 2008-12-16 US US12/316,848 patent/US8288397B2/en active Active
- 2008-12-16 CL CL2008003749A patent/CL2008003749A1/es unknown
- 2008-12-16 EP EP08862830.0A patent/EP2224929B1/en active Active
- 2008-12-16 WO PCT/US2008/013808 patent/WO2009078999A1/en active Application Filing
- 2008-12-16 JP JP2010539471A patent/JP5562865B2/ja active Active
- 2008-12-17 PA PA20088808201A patent/PA8808201A1/es unknown
- 2008-12-17 AR ARP080105488A patent/AR069777A1/es unknown
- 2008-12-17 UY UY31540A patent/UY31540A1/es unknown
-
2012
- 2012-09-12 US US13/611,936 patent/US8637527B2/en active Active
-
2013
- 2013-12-19 US US14/133,848 patent/US9440978B2/en active Active
-
2016
- 2016-09-12 US US15/262,202 patent/US20160376291A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US8288397B2 (en) | 2012-10-16 |
CL2008003749A1 (es) | 2010-01-15 |
EP2224929B1 (en) | 2016-05-04 |
TW200942549A (en) | 2009-10-16 |
EP2224929A1 (en) | 2010-09-08 |
PE20091102A1 (es) | 2009-07-25 |
AR069777A1 (es) | 2010-02-17 |
JP2011506608A (ja) | 2011-03-03 |
EP2224929A4 (en) | 2011-08-03 |
UY31540A1 (es) | 2009-07-17 |
US20130005687A1 (en) | 2013-01-03 |
US9440978B2 (en) | 2016-09-13 |
JP5562865B2 (ja) | 2014-07-30 |
US8637527B2 (en) | 2014-01-28 |
WO2009078999A1 (en) | 2009-06-25 |
US20090156599A1 (en) | 2009-06-18 |
US20140107098A1 (en) | 2014-04-17 |
US20160376291A1 (en) | 2016-12-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PA8808201A1 (es) | Moduladores imidazolo-,oxazolo-, y tiazolopirimidina del trpvi | |
UY30454A1 (es) | Moduladores tiazolopirimidina de trpv1 | |
NI200900159A (es) | Moduladores de 2-aminopirimidina del receptor de histamina h4. | |
ECSP088807A (es) | Tetrahidro-pirimidoazepinas como moduladores del potencial transitorio de receptor vaillinoide 1 (trpv1) | |
CO7101245A2 (es) | Compuestos de benzaldehído sustituidos y métodos para su uso en incrementar la oxigenación del tejido | |
CL2014001158A1 (es) | Compuestos derivados de piperazina alquilados; composicion farmaceutica que los comprende; proceso para preparar la composicion farmaceutica; kit y uso en el tratamiento de trastornos inmunes, cancer, enfermedades cardiovasculares, inflamacion, entre otros. | |
UY34545A (es) | Novedosas dihidropirimidinoisoquinolinonas y composiciones farmacéuticas de las mismas para el tratamiento de trastornos inflamatorios. | |
DOP2017000013A (es) | Procedimiento de preparación de 5-fluoro-1h-pirazolopiridinas sustituidas | |
UY28876A1 (es) | Compuestos de morfolina sustituida y composiciones para el tratamiento de trastornos del sistema nervioso central | |
CL2008003096A1 (es) | Compuestos derivados de piperidino-dihidrotienopirimidinas; inhibidores pde4; composicion farmaceutica que los comprende; y uso en el tratamiento de trastornos o enfermedades de las vias respiratorias o gastrointestinales, como tambien enfermedades inflamatorias de las articulaciones u ojos, entre otras. | |
AR054539A1 (es) | Nuevos anticuerpos anti- madcam | |
BR112014014809A2 (pt) | composições farmacêuticas compreendendo glitazonas e ativadores de nrf2 | |
CR11284A (es) | Sulfonamidas como moduladores de trpm8 | |
ECSP11011276A (es) | Composición farmacéutica, forma farmacéutica, procedimiento para su preparación, métodos de tratamiento y usos de la misma. | |
GT200900230A (es) | 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y uso | |
ECSP11011067A (es) | Compuestos para el tratamiento de enfermedades y desórdenes oftalmológicos | |
CR20120110A (es) | Compuestos heterocíclicos y usos de los mismos | |
UY30479A1 (es) | Moduladores de benzofuro- y benzotienopirimidina del receptor de histamina h4 | |
CR20150067A (es) | Pirazoles sustituidos como bloqueadores del canal de calcio tipo n | |
UY29079A1 (es) | Acidos fenoxiacéticos sustituidos, composiciones que los contienen, procedimientos de preparación y aplicaciones | |
UY32937A (es) | Compuestos y composiciones como moduladores de la actividad de gpr119 | |
UY32312A (es) | 4-azetidinil-1-heteroaril-ciclohexanol antagonistas del ccr2 | |
NI201000214A (es) | Moduladores de diamino-piridina, pirimidina, y piridazina del receptor de la histamina h4. | |
EA201100921A1 (ru) | Соединения, фармацевтические композиции и способы их применения при лечении нарушений обмена веществ | |
CO6331434A2 (es) | Nuevos compuestos |